entertainment -WSS

entertainment

author：knowledge 2025-08-26 10:52:05 - browse：39144

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： FDA greenlights medical device to combat bladder issues

leisure time

WSS

Intellia plays down concerns on accidental germline transmission

CDC concerned about possible undetected monkeypox spread in U.K.

Vivek Ramaswamy made waves in the debate, much as in biotech

Weight bias in eating disorder treatment complicated by new weight loss drugs

The story of mRNA: From a loose idea to a tool that may help curb Covid

WATCH: Why do fingernails fall off when they're damaged?

leisure time

entertainment

explore

Alkermes shareholders re

Intellia plays down concerns on accidental germline transmission

Hollywood unions extend contract negotiations for actors

Abortion policy in the spotlight at Republican debate

Sports medicine is finally prioritizing gender equality

Kellogg’s is going to war over Mexico’s nutrition label rules

George Santos makes 1st court appearance after pleading not guilty to 13 counts

The story of mRNA: From a loose idea to a tool that may help curb Covid

In Memoriam: Notable people who died in 2023

PBMs are inflating the cost of generic drugs. They must be reined in

hotspot

The strategy behind pharma's lawsuits over drug pricing reform

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

WATCH: Why do fingernails fall off when they're damaged?

CDC says it’s too soon to assess risk posed by Covid subvariant

In areas with more Black doctors, Black people live longer

As obesity drug market grows, telehealth companies court payers

focus

leisure time

Wikipedia

explore